Ascelia to highlight MRI oral contrast results at RSNA

By staff writers

November 23, 2021 -- Ascelia Pharma plans to highlight clinical results that demonstrate the efficacy of its Orvigilance oral contrast agent for MRI detection of focal liver lesions at the upcoming RSNA meeting.

Orvigilance is a manganese-based contrast agent designed to enhance MRI scans. Researchers found that it was as effective as a gadolinium-based agent for visualizing and detecting lesions, according to the company.

The U.S. Food and Drug Administration has granted Orvigilance orphan drug designation, and the agent is in a phase III study that consists of 200 patients with severe renal impairment and known or suspected focal liver lesions, according to Ascelia.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking